GlassScriptPhysician profile
Gregory Edward Stempky
NPI 1639123557
$4,722.91
in general payments reported to CMS, 2019-2025
35 companies · $271 in 2025
The $271 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,053 · 2020: $315 · 2021: $1,071 · 2022: $816 · 2023: $748 · 2024: $448 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,467.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,400.16 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $641.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $569.23 | 2019-2025 | |
| Glaxosmithkline, LLC. | $359.12 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $352.26 | 2019-2023 | Qulipta, Vraylar |
| Amgen INC. | $233.68 | 2019-2024 | Repatha, Evenity, Prolia |
| Astellas Pharma US INC | $147.12 | 2019 | |
| Mylan Specialty L.P. | $138.86 | 2019 | |
| Edwards Lifesciences Corporation | $124.62 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Lilly USA, LLC | $117.93 | 2021-2025 | Zepbound, Mounjaro |
| Philips North America LLC | $70.13 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $62.88 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $52.07 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $37.94 | 2020-2025 | Rexulti |
| Shire North American Group INC | $37.13 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $32.09 | 2021 | |
| Merck Sharp & Dohme LLC | $26.13 | 2019 | |
| Abiomed | $24.28 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.12 | 2025 | Caplyta |
| Grifols USA, LLC | $22.97 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $22.91 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.92 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.83 | 2021 | |
| Vanda Pharmaceuticals INC. | $18.97 | 2020 | |
| Lundbeck LLC | $18.94 | 2024 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $18.40 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $17.92 | 2021 | |
| Eisai INC. | $17.57 | 2021 | |
| Allergan, INC. | $16.26 | 2020 | |
| Ibsa Pharma INC. | $15.43 | 2022 | |
| Phathom Pharmaceuticals, INC. | $14.00 | 2024 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $12.82 | 2019 | |
| Horizon Therapeutics Plc | $12.55 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.23 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $10.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Stempky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.